Skip to main content
Fig. 4 | Cancer & Metabolism

Fig. 4

From: An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cells

Fig. 4

Evaluation of the effect of combined DFO + CHC treatment in HeLa cells. A Evaluation of secreted lactate accumulation in the culture medium according to changes in DFO concentration (day 2). *Indicates p < 0.05 compared to control group (one-way ANOVA followed by Tukey’s post hoc test). B Changes observed in cell culture after DFO + CHC treatment — 72 h after administration. Scale bar, 300 μm. C Changes in cell confluence after DFO monotherapy. D Changes in cell confluence after CHC monotherapy. E Changes in cell confluence after DFO + CHC treatment. F Combination index of the DFO + CHC treatment. Fa, fraction affected; CI, combination index. G Dose-effective curve of the DFO + CHC treatment. H Mixture-algebraic estimate of the DFO + CHC treatment, CI > 1 indicates antagonism, CI = 1 indicates additive, CI < 1 indicates synergism. I. J Evaluation of protein expression upon treatment with varying concentrations of DFO + CHC, using WB analysis (day 3)

Back to article page